News

September 18, 2023

CUTISS launches Series C financing round to advance the development of its personalized skin technology, paving the way towards commercialization

Round C to finance the continued development and path to commercialization of denovoSkin™ and Viticell® Phase 2 clinical trial results for lead product denovoSkin™ reached […]
Do you like it?0
Read more
September 12, 2023

THE COMMUNICATIONS STRATEGY GROUP INC., A LIFE SCIENCES CONSULTANCY, ANNOUNCES TWO NEW ADVISORY BOARD MEMBERS REFLECTIVE OF FIRM’S GROWING GLOBAL PRACTICE

Professor Ruth V. Aguilera, PhD, Northeastern University, Trustee Professor at the D’Amore-McKim School of Business, Boston, Massachusetts, USA Mark Treherne, PhD, Chairperson, Monument Therapeutics, Cambridge, […]
Do you like it?0
Read more
August 3, 2023

Aardvark Therapeutics Announces Receipt of FDA Rare Pediatric Disease Designation for Prader-Willi Syndrome and Expands the Ongoing Phase 2 Clinical Trial

The FDA granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme […]
Do you like it?0
Read more
June 20, 2023

Aardvark Therapeutics Announces FDA Orphan Drug Designation Granted to ARD-101, a Novel Drug Candidate for Prader-Willi Syndrome

The FDA granted Aardvark Orphan Drug Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme and unabating […]
Do you like it?0
Read more
1234567
Next page